CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.

• Revenue in USD (TTM)126.62m
• Net income in USD13.83m
• Incorporated2010
• Employees120.00

• Location
  CytomX Therapeutics Inc151 Oyster Point Blvd., Suite 400SOUTH SAN FRANCISCO 94080United StatesUSA
• Phone+1 (650) 515-3185
• Fax+1 (650) 351-0353
• Websitehttps://cytomx.com/